Millie Long, MD, MPH, FACG

UNC Chapel Hill

Poster(s):

• C0400 - Early Symptom Control With Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis in the LUCENT-1 Induction Trial
  Monday, October 24, 2022

  3:00 PM – 5:00 PM ET

• C0401 - Sustained Symptom Control With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis in the LUCENT-2 Maintenance Trial
  Monday, October 24, 2022

  3:00 PM – 5:00 PM ET

• C0402 - Efficacy of Upadacitinib Dose Escalation in a Phase 3 Long-Term Extension Ulcerative Colitis Study
  Monday, October 24, 2022

  3:00 PM – 5:00 PM ET